Aim Economic appraisal can help guide policy‐making for purchasing decisions, and
treatment and management algorithms for health interventions. We conducted a systematic …

Objective To evaluate the costs and benefits associated with the use of abobotulinumtoxinA
(aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) for lower limb spasticity in children …

This consensus paper is derived from a meeting of an international group of 19 neurological
rehabilitation specialists with a combined experience of more than 250 years (range 4–25 …

Background: Injectable botulinum neurotoxins are a mainstay of treatment for pediatric
spasticity. AbobotulinumtoxinA and onabotulinumtoxinA are both injectable toxin therapies …

Introduction Botulinum toxin A is the first-line treatment for localised spasticity. However, the
economic impact of this treatment is not fully known. This study aimed to describe the real …

Introducción: la parálisis cerebral infantil es la causa más frecuente de discapacidad motora
durante la niñez. La toxina botulínica tipo A es considerada una de las principales opciones …

La investigación se enfocó en la modalidad de revisión bibliográfica, dando a conocer los
beneficios de toxina botulínica en el tratamiento fisioterapéutico de la parálisis cerebral …

Cerebral palsy (CP) represents a group of disorders of the mechanisms of movement and
body position, causing limitations of activity, which are caused by non-progressive damage …

Introducción La toxina botulínica A es el tratamiento de elección para la espasticidad
localizada. Sin embargo, no se tiene un conocimiento real de su repercusión económica. El …

A paralisia Cerebral (PC) é uma condição não progressiva e não curável que acomete o
sistema nervoso em formação e pode deixar graves sequelas. O tratamento deve ser …